Not applicableStudy completedNCT02966626What this trial is testingA Real World Experience of Dapagliflozin in Type 2 DiabetesWho this might be right forType2 Diabetes University of Malaya 223
Post-approval studies (Phase 4)UnknownNCT05975528What this trial is testingEffect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 DiabetesWho this might be right forDiabetes MellitusCellular SenescenceSodium-Glucose Transporter 2 Inhibitors Yonsei University 92
Large-scale testing (Phase 3)Ended earlyNCT03933956What this trial is testingMetabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)Who this might be right forDiabetic Nephropathies Singapore General Hospital 2
Post-approval studies (Phase 4)Study completedNCT02360774What this trial is testingMechanisms of Weight Loss With SGLT2 InhibitionWho this might be right forType 2 DiabetesOverweightObesity Beth Israel Deaconess Medical Center 30
Post-approval studies (Phase 4)Looking for participantsNCT06972732What this trial is testingA Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 DiabetesWho this might be right forType 2 Diabetes Boryung Pharmaceutical Co., Ltd 204
Not applicableActive Not RecruitingNCT07198191What this trial is testingSGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort StudyWho this might be right forAcute Myocardial Infarction (AMI)Type 2 Diabetes Mellitus (T2DM) Yonsei University 200,000
Large-scale testing (Phase 3)Study completedNCT05283057What this trial is testingEmpagliflozin in Patients With GlomerulonephritisWho this might be right forGlomerulonephritisProteinuria Kasr El Aini Hospital 50
Not applicableStudy completedNCT02500186What this trial is testingThe Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) InhibitorWho this might be right forDiabetes Melltius, Type 2 Kansai Electric Power Hospital 24
Early research (Phase 1)Study completedNCT03852901What this trial is testingSodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone ProductionWho this might be right forEmpaglifozinPhysiological Effects of DrugsHypoglycemic Agents+1 more National Institute on Aging (NIA) 21
Post-approval studies (Phase 4)Active Not RecruitingNCT06933355What this trial is testingAcute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen TensionWho this might be right forKidney Transplantation RecipientsMagnetic Resonance Imaging (MRI)Sodium-Glucose Transporter 2 Inhibitors+3 more Odense University Hospital 8
Not applicableStudy completedNCT07269197What this trial is testingAssociation of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 DiabetesWho this might be right forNon-Alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2 Josip Juraj Strossmayer University of Osijek 67
Not applicableStudy completedNCT06453161What this trial is testingPre-operative Exposure to SGLT2 Inhibitors and Post-operative Acute Renal Failure in Cardiac Surgery: a Retrospective Monocentric Cohort StudyWho this might be right forAcute Kidney InjuryCardiacSurgery Hospices Civils de Lyon 500
Large-scale testing (Phase 3)Active Not RecruitingNCT05182658What this trial is testingEmpagliflozin in Hypertrophic CardiomyopathyWho this might be right forHypertrophic CardiomyopathyHeart Failure National Institute of Cardiology, Warsaw, Poland 250
Post-approval studies (Phase 4)Not Yet RecruitingNCT07482943What this trial is testingThe Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan ProcedureWho this might be right forFontanHeart FailureDapagliflozin+2 more The University of Hong Kong 30
Testing effectiveness (Phase 2)UnknownNCT04419337What this trial is testingPioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With StrokeWho this might be right forDiabetes MellitusStroke Chang Gung Memorial Hospital 200
Post-approval studies (Phase 4)Study completedNCT05233163What this trial is testingSGLT2 Inhibitors in Transthyretin Amyloid CardiomyopathyWho this might be right forTransthyretin Amyloid Cardiomyopathy Columbia University 15
Post-approval studies (Phase 4)Study completedNCT06825156What this trial is testingMetabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 InhibitorsWho this might be right forAcute Kidney Injury Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 60
Post-approval studies (Phase 4)Active Not RecruitingNCT05590143What this trial is testingProMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2Who this might be right forAcute Kidney InjuryCardiac SurgerySodium-Glucose Transporter 2 Inhibitor Amsterdam UMC 784
Post-approval studies (Phase 4)Study completedNCT02700334What this trial is testingEffect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With PrediabetesWho this might be right forPrediabetesImpaired Fasting GlucoseImpaired Glucose Tolerance University of Guadalajara 24
Testing effectiveness (Phase 2)Study completedNCT05232071What this trial is testingPlacebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes MellitusWho this might be right forNASH - Nonalcoholic SteatohepatitisDiabetes Mellitus, Type 2 Inventiva Pharma 42